{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "31895207", "DateCompleted": {"Year": "2021", "Month": "07", "Day": "28"}, "DateRevised": {"Year": "2021", "Month": "07", "Day": "28"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.1097/MEG.0000000000001485"], "Journal": {"ISSN": "1473-5687", "JournalIssue": {"Volume": "32", "Issue": "2", "PubDate": {"Year": "2020", "Month": "Feb"}}, "Title": "European journal of gastroenterology & hepatology", "ISOAbbreviation": "Eur J Gastroenterol Hepatol"}, "ArticleTitle": "Herbal medicines for the liver: from bench to bedside.", "Pagination": {"StartPage": "148", "EndPage": "158", "MedlinePgn": "148-158"}, "Abstract": {"AbstractText": ["The liver is one of the most complex organs of the human body and is involved in various metabolic processes. Due to its anatomical proximity to the digestive tract, its blood flow, and its contribution to the detoxification process, the liver is susceptible to a wide variety of disorders. Hepatic diseases can be caused by alcoholism, viral infections, malnutrition and xenobiotics, which result in a high frequency of patients with liver disease and subsequent increase in the number of deaths from these diseases, for which adequate treatments are not yet available. Therefore, the search for new alternatives to treat these liver conditions is mandatory. In recent decades, there has been an increase in interest in medicinal herbs due to their safety and hepatoprotective properties that arise from their anti-inflammatory, antioxidant, antifibrotic, antiviral, immunomodulatory and anticancer properties. Epidemiological and clinical studies have shown that the consumption of these compounds is associated with a decrease in the risk of developing liver diseases; thus, medicinal herbs have emerged as a viable option for the treatment of these hepatic pathologies. However, more basic and clinical studies are needed before reaching a final recommendation to treat human liver diseases. This review provides molecular and clinical information on some natural compounds and medicinal herbs that have hepatoprotective effects and could be useful for the treatment of hepatic disorders."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Experimental Hepatology, Department of Pharmacology, Cinvestav-IPN, Mexico City, Mexico."}], "LastName": "Vargas-Pozada", "ForeName": "Eduardo E", "Initials": "EE"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Muriel", "ForeName": "Pablo", "Initials": "P"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't", "Review"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Eur J Gastroenterol Hepatol", "NlmUniqueID": "9000874", "ISSNLinking": "0954-691X"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents"}], "MeshHeadingList": [{"QualifierName": ["therapeutic use"], "DescriptorName": "Anti-Inflammatory Agents"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Liver Diseases"}, {"QualifierName": [], "DescriptorName": "Phytotherapy"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Guicciardi ME, Malhi H, Mott JL, Gores GJ. Apoptosis and necrosis in the liver. Compr Physiol. 2013; 3:977\u20131010"}, {"Citation": "Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005; 115:209\u2013218"}, {"Citation": "Pellicoro A, Ramachandran P, Iredale JP. Reversibility of liver fibrosis. Fibrogenesis Tissue Repair. 2012; 5:S26"}, {"Citation": "Kisseleva T, Brenner DA. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol. 2007; 22Suppl 1S73\u2013S78"}, {"Citation": "Hern\u00e1ndez-Aquino E, Zarco N, Casas-Grajales S, Ramos-Tovar E, Flores-Beltr\u00e1n RE, Arauz J, et al. Naringenin prevents experimental liver fibrosis by blocking tgf\u03b2-smad3 and JNK-smad3 pathways. World J Gastroenterol. 2017; 23:4354\u20134368"}, {"Citation": "Leppert PC, Jayes FL, Segars JH. The extracellular matrix contributes to mechanotransduction in uterine fibroids. Obstet Gynecol Int. 2014; 2014:783289"}, {"Citation": "Malhi H, Guicciardi ME, Gores GJ. Hepatocyte death: a clear and present danger. Physiol Rev. 2010; 90:1165\u20131194"}, {"Citation": "Friedman SL. Liver fibrosis \u2013 from bench to bedside. J Hepatol. 2003; 38Suppl 1S38\u2013S53"}, {"Citation": "Muriel P. Muriel P. The liver: general aspects and epidemiology. Liver Pathophysiology: Therapies & Antioxidants. 2017, Waltham, MA: Elsevier03\u201316"}, {"Citation": "Misra L. Traditional phytomedicinal systems, scientific validations and current popularity as nutraceuticals. Int J Tradit Nat Med. 2013; 2:27\u201375"}, {"Citation": "Mujeeb F, Bajpai P, Pathak N. Phytochemical evaluation, antimicrobial activity, and determination of bioactive components from leaves of aegle marmelos. Biomed Res Int. 2014; 2014:497606"}, {"Citation": "Kennedy DO, Wightman EL. Herbal extracts and phytochemicals: plant secondary metabolites and the enhancement of human brain function. Adv Nutr. 2011; 2:32\u201350"}, {"Citation": "Girish C, Pradhan SC. Muriel P. Herbal drugs on the liver. Liver Pathophysiology: Therapies & Antioxidants. 2017, Waltham, MA: Elsevier605\u2013620"}, {"Citation": "Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014; 4:177"}, {"Citation": "Arauz J, Ramos-Tovar E, Muriel P. Muriel P. Coffee and the liver. Liver Pathophysiology: Therapies & Antioxidants. 2017, Waltham, MA: Elsevier675\u2013685"}, {"Citation": "Caprioli G, Cortese M, Maggi F, Minnetti C, Odello L, Sagratini G, Vittori S. Quantification of caffeine, trigonelline and nicotinic acid in espresso coffee: the influence of espresso machines and coffee cultivars. Int J Food Sci Nutr. 2014; 65:465\u2013469"}, {"Citation": "Casas-Grajales S, Muriel P. Antioxidants in liver health. World J Gastrointest Pharmacol Ther. 2015; 6:59\u201372"}, {"Citation": "Muriel P, Arauz J. Coffee and liver diseases. Fitoterapia. 2010; 81:297\u2013305"}, {"Citation": "Arauz J, Moreno MG, Cort\u00e9s-Reynosa P, Salazar EP, Muriel P. Coffee attenuates fibrosis by decreasing the expression of TGF-\u03b2 and CTGF in a murine model of liver damage. J Appl Toxicol. 2013; 33:970\u2013979"}, {"Citation": "Arauz J, Rivera-Espinoza Y, Shibayama M, Favari L, Flores-Beltr\u00e1n RE, Muriel P. Nicotinic acid prevents experimental liver fibrosis by attenuating the prooxidant process. Int Immunopharmacol. 2015; 28:244\u2013251"}, {"Citation": "Moreno MG, Ch\u00e1vez E, Aldaba-Muruato LR, Segovia J, Vergara P, Tsutsumi V, et al. Coffee prevents ccl(4)-induced liver cirrhosis in the rat. Hepatol Int. 2011; 5:857\u2013863"}, {"Citation": "Batista MN, Carneiro BM, Braga AC, Rahal P. Caffeine inhibits hepatitis C virus replication in vitro. Arch Virol. 2015; 160:399\u2013407"}, {"Citation": "Chen CL, Chang WC, Yi CH, Hung JS, Liu TT, Lei WY, Hsu CS. Association of coffee consumption and liver fibrosis progression in patients with hbeag-negative chronic hepatitis B: a 5-year population-based cohort study. J Formos Med Assoc. 2019; 118:628\u2013635"}, {"Citation": "Wadhawan M, Anand AC. Coffee and liver disease. J Clin Exp Hepatol. 2016; 6:40\u201346"}, {"Citation": "Carrieri MP, Protopopescu C, Marcellin F, Rosellini S, Wittkop L, Esterle L, et al.; ANRS CO13 HEPAVIH Study Group. Protective effect of coffee consumption on all-cause mortality of french HIV-HCV co-infected patients. J Hepatol. 2017; 67:1157\u20131167"}, {"Citation": "Tamura T, Wada K, Konishi K, Goto Y, Mizuta F, Koda S, et al. Coffee, green tea, and caffeine intake and liver cancer risk: a prospective cohort study. Nutr Cancer. 2018; 20:1\u20137"}, {"Citation": "Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology. 2012; 55:429\u2013436"}, {"Citation": "Yaya I, Marcellin F, Costa M, Morlat P, Protopopescu C, Pialoux G, et al. Impact of alcohol and coffee intake on the risk of advanced liver fibrosis: a longitudinal analysis in HIV-HCV coinfected patients (ANRS CO-13 HEPAVIH cohort). Nutrients. 2018; 10:E705"}, {"Citation": "Oliveira Kda S, Buss C, Tovo CV. Association of caffeine intake and liver fibrosis in patients with chronic hepatitis C. Arq Gastroenterol. 2015; 52:4\u20138"}, {"Citation": "Hodge A, Lim S, Goh E, Wong O, Marsh P, Knight V, et al. Coffee intake is associated with a lower liver stiffness in patients with non-alcoholic fatty liver disease, hepatitis C, and hepatitis B. Nutrients. 2017; 9:E56"}, {"Citation": "Chen YP, Lu FB, Hu YB, Xu LM, Zheng MH, Hu ED. A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease. Clin Nutr. 2019; 38:2552\u20132557"}, {"Citation": "V\u00e1zquez-Flores LF, Casas-Grajales S, Hern\u00e1ndez-Aquino E, Vargas-Pozada EE, Muriel P. Muriel P. Antioxidant, antiinflammatory, and antifibrotic properties of quercetin in the liver. Liver Pathophysiology: Therapies & Antioxidants. 2017, Waltham, MA: Elsevier653\u2013674"}, {"Citation": "Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr. 2001; 74:418\u2013425"}, {"Citation": "Anand David AV, Arulmoli R, Parasuraman S. Overviews of biological importance of quercetin: a bioactive flavonoid. Pharmacogn Rev. 2016; 10:84\u201389"}, {"Citation": "Am\u00e1lia PM, Possa MN, Augusto MC, Francisca LS. Quercetin prevents oxidative stress in cirrhotic rats. Dig Dis Sci. 2007; 52:2616\u20132621"}, {"Citation": "Pavanato A, Tu\u00f1\u00f3n MJ, S\u00e1nchez-Campos S, Marroni CA, Llesuy S, Gonz\u00e1lez-Gallego J, Marroni N. Effects of quercetin on liver damage in rats with carbon tetrachloride-induced cirrhosis. Dig Dis Sci. 2003; 48:824\u2013829"}, {"Citation": "Kabirifar R, Ghoreshi ZA, Safari F, Karimollah A, Moradi A, Eskandari-Nasab E. Quercetin protects liver injury induced by bile duct ligation via attenuation of rac1 and NADPH oxidase1 expression in rats. Hepatobiliary Pancreat Dis Int. 2017; 16:88\u201395"}, {"Citation": "de David C, Rodrigues G, Bona S, Meurer L, Gonz\u00e1lez-Gallego J, Tu\u00f1\u00f3n MJ, Marroni NP. Role of quercetin in preventing thioacetamide-induced liver injury in rats. Toxicol Pathol. 2011; 39:949\u2013957"}, {"Citation": "Casas-Grajales S, V\u00e1zquez-Flores LF, Ramos-Tovar E, Hern\u00e1ndez-Aquino E, Flores-Beltr\u00e1n RE, Cerda-Garc\u00eda-Rojas CM, et al. Quercetin reverses experimental cirrhosis by immunomodulation of the proinflammatory and profibrotic processes. Fundam Clin Pharmacol. 2017; 31:610\u2013624"}, {"Citation": "Domitrovi\u0107 R, Jakovac H, Vasiljev Marchesi V, Vladimir-Kne\u017eevi\u0107 S, Cvijanovi\u0107 O, Tadi\u0107 Z, et al. Differential hepatoprotective mechanisms of rutin and quercetin in ccl(4)-intoxicated BALB/cn mice. Acta Pharmacol Sin. 2012; 33:1260\u20131270"}, {"Citation": "Li X, Jin Q, Yao Q, Xu B, Li L, Zhang S, Tu C. The flavonoid quercetin ameliorates liver inflammation and fibrosis by regulating hepatic macrophages activation and polarization in mice. Front Pharmacol. 2018; 9:72"}, {"Citation": "Liu S, Tian L, Chai G, Wen B, Wang B. Targeting heme oxygenase-1 by quercetin ameliorates alcohol-induced acute liver injury via inhibiting NLRP3 inflammasome activation. Food Funct. 2018; 9:4184\u20134193"}, {"Citation": "Wan Y, Tang MH, Chen XC, Chen LJ, Wei YQ, Wang YS. Inhibitory effect of liposomal quercetin on acute hepatitis and hepatic fibrosis induced by concanavalin A. Braz J Med Biol Res. 2014; 47:655\u2013661"}, {"Citation": "Marcolin E, Forgiarini LF, Rodrigues G, Tieppo J, Borghetti GS, Bassani VL, et al. Quercetin decreases liver damage in mice with non-alcoholic steatohepatitis. Basic Clin Pharmacol Toxicol. 2013; 112:385\u2013391"}, {"Citation": "Lu NT, Crespi CM, Liu NM, Vu JQ, Ahmadieh Y, Wu S, et al. A phase I dose escalation study demonstrates quercetin safety and explores potential for bioflavonoid antivirals in patients with chronic hepatitis C. Phytother Res. 2016; 30:160\u2013168"}, {"Citation": "Abenavoli L, Milic N. Muriel P. Silymarin for liver disease. Liver Pathophysiology: Therapies & Antioxidants. 2017, Waltham, MA: Elsevier621\u2013631"}, {"Citation": "Colica C, Boccuto L, Abenavoli L. Silymarin: an option to treat non-alcoholic fatty liver disease. World J Gastroenterol. 2017; 23:8437\u20138438"}, {"Citation": "Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010; 24:1423\u20131432"}, {"Citation": "Perumpail B, Li A, Iqbal U, Sallam S, Shah N, Kwong W, et al. Potential therapeutic benefits of herbs and supplements in patients with NAFLD. Diseases. 2018; 6:E80"}, {"Citation": "Tajmohammadi A, Razavi BM, Hosseinzadeh H. Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: a review. Phytother Res. 2018; 32:1933\u20131949"}, {"Citation": "Esmaeil N, Anaraki SB, Gharagozloo M, Moayedi B. Silymarin impacts on immune system as an immunomodulator: one key for many locks. Int Immunopharmacol. 2017; 50:194\u2013201"}, {"Citation": "Chen IS, Chen YC, Chou CH, Chuang RF, Sheen LY, Chiu CH. Hepatoprotection of silymarin against thioacetamide-induced chronic liver fibrosis. J Sci Food Agric. 2012; 92:1441\u20131447"}, {"Citation": "Gharbia S, Balta C, Herman H, Rosu M, V\u00e1radi J, B\u00e1cskay I, et al. Enhancement of silymarin anti-fibrotic effects by complexation with hydroxypropyl (HPBCD) and randomly methylated (RAMEB) \u03b2-cyclodextrins in a mouse model of liver fibrosis. Front Pharmacol. 2018; 9:883"}, {"Citation": "Ou Q, Weng Y, Wang S, Zhao Y, Zhang F, Zhou J, Wu X. Silybin alleviates hepatic steatosis and fibrosis in NASH mice by inhibiting oxidative stress and involvement with the nf-\u03bab pathway. Dig Dis Sci. 2018; 63:3398\u20133408"}, {"Citation": "Cicero A, Colletti A, Bellentani S. Nutraceutical approach to non-alcoholic fatty liver disease (NAFLD): the available clinical evidence. Nutrients. 2018; 10:E1153"}, {"Citation": "Abenavoli L, Izzo AA, Mili\u0107 N, Cicala C, Santini A, Capasso R. Milk thistle (Silybum marianum): a concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother Res. 2018; 32:2202\u20132213"}, {"Citation": "Li Y, Mu M, Yuan L, Zeng B, Lin S. Challenges in the early diagnosis of patients with acute liver failure induced by amatoxin poisoning: two case reports. Medicine (Baltimore). 2018; 97:e11288"}, {"Citation": "Fathalah WF, Abdel Aziz MA, Abou El Soud NH, El Raziky MES. High dose of silymarin in patients with decompensated liver disease: a randomized controlled trial. J Interferon Cytokine Res. 2017; 37:480\u2013487"}, {"Citation": "de Avelar CR, Pereira EM, de Farias Costa PR, de Jesus RP, de Oliveira LPM. Effect of silymarin on biochemical indicators in patients with liver disease: systematic review with meta-analysis. World J Gastroenterol. 2017; 23:5004\u20135017"}, {"Citation": "Aller R, Izaola O, G\u00f3mez S, Tafur C, Gonz\u00e1lez G, Berroa E, et al. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study. Eur Rev Med Pharmacol Sci. 2015; 19:3118\u20133124"}, {"Citation": "Yen FL, Wu TH, Lin LT, Cham TM, Lin CC. Naringenin-loaded nanoparticles improve the physicochemical properties and the hepatoprotective effects of naringenin in orally-administered rats with ccl(4)-induced acute liver failure. Pharm Res. 2009; 26:893\u2013902"}, {"Citation": "Hernandez-Aquino E, Muriel P. Muriel P. Naringenin and the liver. Liver Pathophysiology: Therapies & Antioxidants. 2017, Waltham, MA: Elsevier633\u2013651"}, {"Citation": "Lee MH, Yoon S, Moon JO. The flavonoid naringenin inhibits dimethylnitrosamine-induced liver damage in rats. Biol Pharm Bull. 2004; 27:72\u201376"}, {"Citation": "Jayaraman J, Veerappan M, Namasivayam N. Potential beneficial effect of naringenin on lipid peroxidation and antioxidant status in rats with ethanol-induced hepatotoxicity. J Pharm Pharmacol. 2009; 61:1383\u20131390"}, {"Citation": "Prabu SM, Shagirtha K, Renugadevi J. Naringenin in combination with vitamins C and E potentially protects oxidative stress-mediated hepatic injury in cadmium-intoxicated rats. J Nutr Sci Vitaminol (Tokyo). 2011; 57:177\u2013185"}, {"Citation": "Arul D, Subramanian P. Naringenin (citrus flavonone) induces growth inhibition, cell cycle arrest and apoptosis in human hepatocellular carcinoma cells. Pathol Oncol Res. 2013; 19:763\u2013770"}, {"Citation": "Goldwasser J, Cohen PY, Lin W, Kitsberg D, Balaguer P, Polyak SJ, et al. Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. J Hepatol. 2011; 55:963\u2013971"}, {"Citation": "Hern\u00e1ndez-Aquino E, Muriel P. Beneficial effects of naringenin in liver diseases: molecular mechanisms. World J Gastroenterol. 2018; 24:1679\u20131707"}, {"Citation": "Salehi B, Fokou P, Sharifi-Rad M, Zucca P, Pezzani R, Martins N, et al. The therapeutic potential of naringenin: a review of clinical trials. Pharmaceuticals (Basel). 2019; 12:E11"}, {"Citation": "Gon\u00e7alves D, Lima C, Ferreira P, Costa P, Costa A, Figueiredo W, Cesar T. Orange juice as dietary source of antioxidants for patients with hepatitis C under antiviral therapy. Food Nutr Res. 2017; 61:1296675"}, {"Citation": "Ammon HP, Wahl MA. Pharmacology of curcuma longa. Planta Med. 1991; 57:1\u20137"}, {"Citation": "Srinivas L, Shalini VK, Shylaja M. Turmerin: a water soluble antioxidant peptide from turmeric [curcuma longa]. Arch Biochem Biophys. 1992; 292:617\u2013623"}, {"Citation": "Reyes-Gordillo K, Shah R, Lakshman MR, Flores-Beltran RE, Muriel P. Muriel P. Hepatoprotective properties of curcumin. Liver Pathophysiology: Therapies & Antioxidants. 2017, Waltham, MA: Elsevier687\u2013704"}, {"Citation": "Reyes-Gordillo K, Segovia J, Shibayama M, Tsutsumi V, Vergara P, Moreno MG, Muriel P. Curcumin prevents and reverses cirrhosis induced by bile duct obstruction or CCl4 in rats: role of TGF-beta modulation and oxidative stress. Fundam Clin Pharmacol. 2008; 22:417\u2013427"}, {"Citation": "Reyes-Gordillo K, Segovia J, Shibayama M, Vergara P, Moreno MG, Muriel P. Curcumin protects against acute liver damage in the rat by inhibiting NF-kappab, proinflammatory cytokines production and oxidative stress. Biochim Biophys Acta. 2007; 1770:989\u2013996"}, {"Citation": "Bruck R, Ashkenazi M, Weiss S, Goldiner I, Shapiro H, Aeed H, et al. Prevention of liver cirrhosis in rats by curcumin. Liver Int. 2007; 27:373\u2013383"}, {"Citation": "Wu P, Huang R, Xiong YL, Wu C. Protective effects of curcumin against liver fibrosis through modulating DNA methylation. Chin J Nat Med. 2016; 14:255\u2013264"}, {"Citation": "Xu MX, Zhao L, Deng C, Yang L, Wang Y, Guo T, et al. Curcumin suppresses proliferation and induces apoptosis of human hepatocellular carcinoma cells via the wnt signaling pathway. Int J Oncol. 2013; 43:1951\u20131959"}, {"Citation": "Afrin R, Arumugam S, Rahman A, Wahed MI, Karuppagounder V, Harima M, et al. Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-\u03bab translocation. Int Immunopharmacol. 2017; 44:174\u2013182"}, {"Citation": "Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, Sahebkar A. Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial. Phytother Res. 2016; 30:1540\u20131548"}, {"Citation": "Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mend\u00eda LE, Sahebkar A. Efficacy and safety of phytosomal curcumin in non-alcoholic fatty liver disease: a randomized controlled trial. Drug Res (Stuttg). 2017; 67:244\u2013251"}, {"Citation": "Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the indian solid gold. Adv Exp Med Biol. 2007; 595:1\u201375"}, {"Citation": "Hewlings S, Kalman D. Curcumin: a review of its\u2019 effects on human health. Foods. 2017; 6:E92"}, {"Citation": "Xu L, Botchway BOA, Zhang S, Zhou J, Liu X. Inhibition of NF-\u03bab signaling pathway by resveratrol improves spinal cord injury. Front Neurosci. 2018; 12:690"}, {"Citation": "Szkudelski T, Szkudelska K. Potential of resveratrol in mitigating metabolic disturbances induced by ethanol. Biomed Pharmacother. 2018; 101:579\u2013584"}, {"Citation": "Ch\u00e1vez E, Galicia-Moreno M, Muriel P. Muriel P. Are N-Acetylcysteine and resveratrol effective treatments for liver disease? Liver Pathophysiology: Therapies & Antioxidants. 2017, Waltham, MA: Elsevier729\u2013742"}, {"Citation": "Rivera H, Shibayama M, Tsutsumi V, Perez-Alvarez V, Muriel P. Resveratrol and trimethylated resveratrol protect from acute liver damage induced by CCl4 in the rat. J Appl Toxicol. 2008; 28:147\u2013155"}, {"Citation": "Ch\u00e1vez E, Reyes-Gordillo K, Segovia J, Shibayama M, Tsutsumi V, Vergara P, et al. Resveratrol prevents fibrosis, NF-kappaB activation and TGF-beta increases induced by chronic CCl4 treatment in rats. J Appl Toxicol. 2008; 28:35\u201343"}, {"Citation": "Tian Y, Wu B, Li X, Jin X, Zhang F, Jiang C, et al. The resveratrol alleviates the hepatic toxicity of cuso4 in the rat. Biol Trace Elem Res. 2019; 187:464\u2013471"}, {"Citation": "Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014; 34:837\u2013843"}, {"Citation": "Asghari S, Rafraf M, Farzin L, Asghari-Jafarabadi M, Ghavami SM, Somi MH. Effects of pharmacologic dose of resveratrol supplementation on oxidative/antioxidative status biomarkers in nonalcoholic fatty liver disease patients: a randomized, double-blind, placebo-controlled trial. Adv Pharm Bull. 2018; 8:307\u2013317"}, {"Citation": "Elgebaly A, Radwan IA, AboElnas MM, Ibrahim HH, Eltoomy MF, Atta AA, et al. Resveratrol supplementation in patients with non-alcoholic fatty liver disease: systematic review and meta-analysis. J Gastrointestin Liver Dis. 2017; 26:59\u201367"}, {"Citation": "Kantartzis K, Fritsche L, Bombrich M, Machann J, Schick F, Staiger H, et al. Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Obes Metab. 2018; 20:1793\u20131797"}, {"Citation": "Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O\u2019Moore-Sullivan TM, Lee P, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014; 12:2092\u2013103.e1"}, {"Citation": "Malaguarnera G, Pennisi M, Bertino G, Motta M, Borz\u00ec A, Vicari E, et al. Resveratrol in patients with minimal hepatic encephalopathy. Nutrients. 2018; 10:E329"}, {"Citation": "Ramesh K, Singh V, Megeji NW. Cultivation of stevia [Stevia rebaudiana (Bert.) Bertoni]: a comprehensive review. Adv Agron. 2006; 89:137\u2013177"}, {"Citation": "Momtazi-Borojeni AA, Esmaeili SA, Abdollahi E, Sahebkar A. A review on the pharmacology and toxicology of steviol glycosides extracted from Stevia rebaudiana. Curr Pharm Des. 2017; 23:1616\u20131622"}, {"Citation": "Gupta E, Purwar S, Sundaram S, Rai GK. Nutritional and therapeutic values of Stevia rebaudiana: a review. J Med Plants Res. 2013; 7:3343\u20133353"}, {"Citation": "Ramos-Tovar E, Muriel P. Muriel P. Stevia as a putative hepatoprotector. Liver Pathophysiology: Therapies & Antioxidants. 2017, Waltham, MA: Elsevier715\u2013727"}, {"Citation": "Ramos-Tovar E, Hern\u00e1ndez-Aquino E, Casas-Grajales S, Buendia-Monta\u00f1o LD, Galindo-G\u00f3mez S, Camacho J, et al. Stevia prevents acute and chronic liver injury induced by carbon tetrachloride by blocking oxidative stress through nrf2 upregulation. Oxid Med Cell Longev. 2018; 2018:3823426"}, {"Citation": "Ramos-Tovar E, Buendia-Monta\u00f1o LD, Galindo-G\u00f3mez S, Hern\u00e1ndez-Aquino E, Tsutsumi V, Muriel P. Stevia prevents experimental cirrhosis by reducing hepatic myofibroblasts and modulating molecular profibrotic pathways. Hepatol Res. 2019; 49:212\u2013223"}, {"Citation": "Ramos-Tovar E, Flores-Beltr\u00e1n RE, Galindo-G\u00f3mez S, Vera-Aguilar E, Diaz-Ruiz A, Montes S, et al. Stevia rebaudiana tea prevents experimental cirrhosis via regulation of NF-\u03baB, Nrf2, transforming growth factor beta, Smad7, and hepatic stellate cell activation. Phytother Res. 2018; 32:2568\u20132576"}, {"Citation": "Ramos-Tovar E, Flores-Beltr\u00e1n RE, Galindo-G\u00f3mez S, Camacho J, Tsutsumi V, Muriel P. An aqueous extract of Stevia rebaudiana variety morita II prevents liver damage in a rat model of cirrhosis that mimics the human disease. Ann Hepatol. 2019; 18:472\u2013479"}, {"Citation": "Ramos-Tovar E, Casas-Grajales S, Hern\u00e1ndez-Aquino E, Flores-Beltr\u00e1n RE, Galindo-G\u00f3mez S, Vera-Aguilar E, et al. Cirrhosis induced by thioacetamide is prevented by stevia. Molecular mechanisms. J Funct Foods. 2019; 52:552\u2013564"}, {"Citation": "Casas-Grajales S, Alvarez-Suarez D, Ramos-Tovar E, Dayana Buend\u00eda-Monta\u00f1o L, Reyes-Gordillo K, Camacho J, et al. Stevioside inhibits experimental fibrosis by down-regulating profibrotic smad pathways and blocking hepatic stellate cell activation. Basic Clin Pharmacol Toxicol. 2019; 124:670\u2013680"}, {"Citation": "S L, Chaudhary S, R S R. Hydroalcoholic extract of Stevia rebaudiana bert. Leaves and stevioside ameliorates lipopolysaccharide induced acute liver injury in rats. Biomed Pharmacother. 2017; 95:1040\u20131050"}, {"Citation": "Wang Y, Li L, Wang Y, Zhu X, Jiang M, Song E, Song Y. New application of the commercial sweetener rebaudioside a as a hepatoprotective candidate: induction of the nrf2 signaling pathway. Eur J Pharmacol. 2018; 822:128\u2013137"}, {"Citation": "Casas-Grajales S, Reyes-Gordillo K, Cerda-Garc\u00eda-Rojas CM, Tsutsumi V, Lakshman MR, Muriel P. Rebaudioside A administration prevents experimental liver fibrosis: an in vivo and in vitro study of the mechanisms of action involved. J Appl Toxicol. 2019; 39:1118\u20131131"}, {"Citation": "Holvoet P, Rull A, Garc\u00eda-Heredia A, L\u00f3pez-Sanrom\u00e0 S, Geeraert B, Joven J, Camps J. Stevia-derived compounds attenuate the toxic effects of ectopic lipid accumulation in the liver of obese mice: a transcriptomic and metabolomic study. Food Chem Toxicol. 2015; 77:22\u201333"}], "ReferenceList": []}], "History": [{"Year": "2020", "Month": "1", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "1", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "7", "Day": "29", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["31895207", "10.1097/MEG.0000000000001485", "00042737-202002000-00004"]}}], "PubmedBookArticle": []}